Highlights
About
Robotics-assisted Medical Technologies
Microbot Medical specializes in transformational robotic technologies, focused primarily on the endovascular space. Its LIBERTY Robotic System is the world’s first single-use endovascular robotic system focused on increasing access to robotic technology and revolutionizing the way endovascular procedures are performed.
LIBERTY is the first ever single-use endovascular surgical robotic system designed to streamline endovascular procedures.
In August 2016, U.S.-based StemCells merged with Microbot Medical. In May 2018, the company announced its acquisition of a novel, patent-protected technology from CardioSert. Microbot Medical is now the owner of this technology, including all research and development information, technical know-how, and intellectual property.
Identity
| Name | Microbot Medical |
|---|---|
| Slug | microbot-medical |
| Type / kind | startup |
| Crunchbase ID | microbot-medical |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJnEi5sKDA |
Status
| Status | active |
|---|---|
| Status reason | Public on NASDAQ on Nov 2016; |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Yokne'am Illit |
| HQ address | HaYozma St 6, Yokne'am Illit, Israel |
Web & social
Classifications
Funding
| Total raised | $90.5M |
|---|---|
| Current stage | Public |
| Market cap | $134.3M |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}